duchenne muscular dystrophy sarepta - Search News

News

Duchenne muscular dystrophy, gene therapy

Following second patient death, Duchenne muscular dystrophy families deserve answers about Elevidys

Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t getting answers from Sarepta.

Associated Press News on MSN · 3d

Second patient death reported with gene therapy for muscular dystrophy

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.

Seeking Alpha on MSN · 3d

2nd death reported in Sarepta gene therapy trial for Duchenne muscular dystrophy

Sarepta Therapeutics (NASDAQ:SRPT) reported a second fatality from acute liver failure in a patient treated with its gene therapy, Elevidys, designed for Duchenne muscular dystrophy (DMD), Bloomberg News reported Sunday.

What’s next for Sarepta Therapeutics with gene therapy under fire?

The death of a boy with Duchenne muscular dystrophy, tied to a gene therapy, is above all a tragedy. But it is also ...

3d

Why Sarepta Therapeutics (SRPT) Stock Is Down Today

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a ...

Managed Healthcare Executive3d

Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results